Specifically, out of a total of 506 patients with GI cancers, 381 underwent MSI testing; among 228 GC patients, 164 had HER-2 status evaluated; and among 151 CRC patients, 105 completed K-RAS testing. The gene discussed is ERBB2; the disease is gastric cancer.